DrFirst Demonstrates The Nation's First Electronic Prescribing Of Controlled Substances (EPCS) System At AHRQ On June 3, 2010
Main Category: IT / Internet / E-mailArticle Date: 02 Jun 2010 - 14:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Today marks a major milestone in healthcare IT history. The DEA has officially lifted the restrictions against the use of electronic prescribing for controlled substances (schedule II - schedule V), which have been the single greatest barrier to e-prescribing adoption over the last 10 years. DrFirst is proud to announce that on Thursday, June 3rd, it will herald this new era in e-prescribing with a public demonstration of the nation's first end-to-end electronic controlled substance prescribing system at the 2010 AHRQ Annual Health IT Grantee and Contractor meeting in Washington, DC. This system has been operational in Berkshire County, MA since September 14, 2009. DrFirst will also publically release key details of the technology involved in this ground-breaking application.
Controlled substances make up roughly 11% of prescriptions written in the United States and are written by approximately 90% of providers. The inability to write a controlled drug electronically created the need for a provider to implement two office workflows: one for electronic prescriptions and one for controlled substances that were hand-signed and hand-delivered. This inconsistency in workflow ultimately defeated the efficiency that electronic prescribing otherwise promised to bring to the practice.
After talks at a 2006 symposium held by the DEA, DrFirst became involved in discussions regarding how to build a safe and measurable way to overcome the security and accountability issues. This meeting, along with funding from the Agency for Healthcare Research and Quality (AHRQ) spawned the Electronic Prescribing of Controlled Substances (EPCS) pilot program.
"During the study DrFirst, along with the other participants, was able to successfully demonstrate that we have the technology and capability to make the process efficient, safe, and secure," said Peter N. Kaufman, MD, CMO of DrFirst, Inc. "Security issues have long clouded the issue of e-prescribing controlled substances. We created a process that not only uses tight security for prescribers using the system, but uses the current trusted network between the e-prescribing or EMR application and the pharmacy. This new Rcopia system will finally allow providers to efficiently adopt an optimal e-prescribing workflow in their offices with a complete e-prescribing solution."
The DEA's regulations which take effect today allow prescribers the option to write prescriptions for controlled substances electronically and allow pharmacies to receive, dispense, and archive these electronic prescriptions. The regulations are an addition to existing rules and will maintain a closed system of controls on controlled substances dispensing. The regulations will reduce paperwork for pharmacies registered by DEA and have the potential to reduce prescription forgery. Additionally, the regulations have the potential to reduce the number of prescription errors and will help integrate prescription records into other medical records.
Now that EPCS is legal, per the DEA IFR, the HIT industry must catch up on implementation of compliant systems. Dr. Thomas Sullivan, past president of the Massachusetts Medical Society, will be presenting the nation's first functional EPCS system by DrFirst at the AHRQ Annual Meeting session entitled "Session 1.6 Demonstration of Electronic Prescribing" from 9:15-10:30am. Following the demonstration at AHRQ, DrFirst will publically release information on the foundation technology behind its working system. This will include a brief video of the demonstration and a discussion of the technology located here.
Source
DrFirst
Visit our it / internet / e-mail section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/190650.php>
APA
http://www.medicalnewstoday.com/releases/190650.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



